Trials / Completed
CompletedNCT02765204
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Uppsala University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if Dapagliflozin has direct effect on alpha cell glucagon release.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | |
| DRUG | Saxagliptin | |
| DRUG | Glucose |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2016-05-06
- Last updated
- 2016-12-12
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02765204. Inclusion in this directory is not an endorsement.